Great to see this out- congrats Yaacov Lawrence Md, Laura Dawson et al. Retroperitoneal pain due to tumor celiac plexus involvement can be debilitating & narcotic refractory 25 Gy x 1 improving pain in 53% is remarkable! RCT of RT v celiac block hopefully forthcoming NRG Oncology🤞1/3

Words cannot describe how profoundly sad I am to share the news of Dr. Shekinah Elmore's death this week. Shekinah was a SPECTACULAR human with profound wisdom, an incredible generosity of spirit, & a heart of kindness that lifted us all up. gofundme.com/f/honoring-dr-…

GI oncology friends - ever wish in tumor board there were data indicating that Y-90 may not be the best treatment for arterially hypoperfused tumors in primary hepatic malignancies? Makes sense - mean Y-90 energy penetration is 2.5 mm. Take a look! #SBRT frontiersin.org/journals/oncol…

Congrats Jay Detsky MD! ‘Look forward to your talk Radiation Oncology

Fellow radiation therapist/educator colleagues… check out the link below and join our internationally renowned Radiation Oncology #MRS as the next program director!!! CAMRT/ACTRM SCoR Members ASMIRT ESTRO #RTT APRTiCoP

Looking forward to seeing past and present students and faculty! David Kirsch, MD, PhD arjun sahgal

“Radiotherapy is used in 50% of cancer patients, but only 5% of funding goes towards radiotherapy research”. A challenge around the world. Congrats Anthony Chalmers 💙.

Congratulations Laura Dawson Radiation Medicine Program Princess Margaret Cancer Centre University Health Network Radiation Oncology and colleagues across Canada for publishing CCTG HE1 in The Lancet Oncology establishing single fraction RT as an effective palliative treatment for painful liver cancer. CCTG thelancet.com/journals/lanon…

Big congrats to Laura Dawson & team for completing this symptom-based, palliative radiotherapy RCT! 8Gy x 1 ~whole liver RT improves pain in 67% Agree that all patients fitting study criteria should be offered this simple, convenient, safe & cost-effective treatment.

Online First: #Palliative #radiotherapy versus best supportive care in patients with painful #hepaticcancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study #radonc thelancet.com/journals/lanon…

Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study out on The Lancet Oncology thelancet.com/journals/lanon… This phase 3 randomized controlled trial (CCTG HE1) aimed to

#CCTG HE1 trial The Lancet Oncology publication shows that palliative radiation improves pain management for liver cancer patients and should be a standard palliative intervention. Congrats to Laura Dawson University Health Network Princess Margaret Cancer Centre thx to Research at Canadian Cancer Society Canadian Cancer Society bit.ly/4dQvP81

Fantastic data - we implemented this treatment immediately after the results were presented at ASCO GI and are impressed by the outcomes. Congrats to Laura Dawson !!!!

🚨CCTG HE.1🚨 Phase 3 RCT refractory HCC or liver metastasis with associated pain > 4/10 Randomized: Best Supportive care (BSC) vs. Single fraction palliative liver RT + BSC 🔥RT associated with ✅⬆️ Pain response ✅⬆️ QoL ✅ Trend to ⬆️ OS Congrats to Laura Dawson !!

Congrats Andrea Bezjak! David Kirsch, MD, PhD Radiation Oncology The Princess Margaret Cancer Foundation Princess Margaret Cancer Centre Laura Dawson

Congrats to Brad Wouters 🇨🇦 ! A giant in our field and beyond.

Thanks Curtiland Deville for being the #CAROASM2024 invited lecturer. Inspirational talk on ‘The path forward toward health #EDI in radiation oncology in a post- 2020 Era’. ‘Appreciate you sharing lifetime efforts and tips to help move the field forward. ASTRO

Congratulations Brad Wouters 🇨🇦 So well deserved!

Presented at #ESMO24: Among patients with limited-stage small-cell lung cancer, overall and progression-free survival were significantly longer with durvalumab adjuvant therapy added to standard concurrent chemoradiotherapy. Full ADRIATIC trial results: nej.md/4d0eZ5m

Updated data for atezo + bev vs surveillance in resected or ablated high risk HCC #ESMO24 🔎IMbrave050 👉RFS 33.2 vs 36 mo, HR 0.9 👉OS: HR: 1.26 🧐Benefit not sustained! Disappointing.. 🧐Caveat of (too) early read outs… ESMO - Eur. Oncology #ESMOAmbassadors @ILCA EASL Education